Kathy (on for Akash Tewari)'s questions to Biontech SE (BNTX) leadership • Q3 2024
Question
Kathy, on behalf of Akash Tewari, asked how adverse events for BNT327 compare to historical data for co-administered VEGF and PD-L1 drugs and questioned the rationale for pursuing a first-line NSCLC trial in an all-comers population.
Answer
CEO Dr. Ugur Sahin stated that with over 700 patients treated, BNT327 shows a reduced side effect profile compared to historical bevacizumab data, with significantly lower rates of bleeding and hypertension. He explained the all-comer strategy for NSCLC is based on BNT327 showing clinical activity in both PD-L1 positive and negative populations, potentially overcoming the limitations of traditional checkpoint inhibitors.